We are live on ! Find out more

PBLS

Parabilis Medicines Inc

PBLS

Market cap $5.16B

41.73 USD

+0.85

2.08%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

41.73

0.00

0%

1 day

2.08%

5 days

12.6%

1 month

6.05%

3 months

61.43%

6 months

32.06%

Year to date

32.06%

1 year

32.06%

5 years

32.06%

10 years

32.06%

About: Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D.

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L.

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus competitors.

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Primary Markets Group June 2026 U.S. IPO Update

The U.S. IPO market shattered records in June 2026, propelled by the ‘out of this world' debut of Space Exploration Technologies Corp. The month saw 19 IPOs raising a staggering $97.9 billion, which was a dramatic increase from the $13.1 billion raised across 12 deals in May and the $4.2 billion across 10 IPOs in June 2025. Looking at pricing performance, the best first-day performance came from healthcare firm Parabilis Medicines, Inc., which increased 58.0% after pricing its offering above its initial filing range.

Primary Markets Group June 2026 U.S. IPO Update

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

The Motley Fool

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed.

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

The Motley Fool

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

Director Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share. This activity increased his ownership to 30,000 shares, held through an entity he controls.

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

The Motley Fool

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

Parabilis and another recent IPO stock each raised more than Moderna -- which had previously been the biggest biotech IPO. Parabilis' technology could be a game changer and potentially used across treatment areas.

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

See News Rankings

Price charts implemented using Lightweight Charts™